论文部分内容阅读
目的:观察胰激肽原酶联合黄芪治疗糖尿病肾病的疗效。方法:78例糖尿病肾病患者随机分为2组,对照组采用口服胰激肽原酶治疗,治疗组在对照组治疗基础上加用黄芪注射液,2组疗程均为4周。观察2组疗效及24h微量尿蛋白排泄率(UPE)、尿白蛋白(Alb)、尿球蛋白(β2-MG)、尿糖蛋白(THP)、血清肌酐(Scr)和尿素氮(BUN)等指标的变化。结果:治疗后各项观察指标均显著下降(P<0.01),治疗组UPE、Alb、β2-MG、THP下降更为明显。2组总有效率分别为87.2%、66.7%(P<0.05)。结论:胰激肽原酶联合黄芪治疗糖尿病肾病对减少蛋白尿漏出有较好疗效。
Objective: To observe the therapeutic effect of pancreatic kallikrein combined with Astragalus on diabetic nephropathy. Methods: 78 patients with diabetic nephropathy were randomly divided into two groups. The control group was treated with oral pancreatic kallikrein. The treatment group was given astragalus injection on the basis of the control group. The two courses of treatment were 4 weeks. The effects of two groups were observed and the levels of urinary albumin (ALB), urinary globulin (ALB), urinary albumin (THP), serum creatinine (Scr) and blood urea nitrogen (BUN) Changes in indicators. Results: After treatment, all the indexes were significantly decreased (P <0.01), and the decrease of UPE, Alb, β2-MG and THP in treatment group was more obvious. The total effective rate in 2 groups was 87.2% and 66.7% respectively (P <0.05). Conclusion: The combination of pancreatic kallikrein and astragalus membranaceus for the treatment of diabetic nephropathy has a good effect on reducing proteinuria and leakage.